Rural Hospital Closures Impact Breast Cancer Care Access
Explore how rural hospital closures are hindering access to essential breast cancer care services, impacting screening, diagnosis, and treatment for patients.
Expansion of Medicare Coverage for Immunotherapy Monitoring
Personalis Inc expands Medicare coverage for immunotherapy monitoring, enhancing cancer treatment precision and patient care with advanced diagnostics.
Challenges in Health Insurance Coverage for Rare Cancer Treatments
Explore the challenges of health insurance coverage for rare cancers, focusing on Axa's policy denials and legislative efforts for better patient support.
Challenges with Medicare Advantage: Impact on Cancer Treatment Access
Explore the challenges facing cancer patients under Medicare Advantage, including network exclusions and the complexities of Medigap insurance.
Moffitt Cancer Center Excluded from Humana and Aetna's Medicare Advantage Plans
Moffitt Cancer Center is excluded from Humana and Aetna Medicare Advantage plans, impacting coverage options and costs for enrollees. Learn more!
Advancements in Cancer Care: Impact on Insurance Industry Dynamics
Explore how recent advancements in cancer care impact the insurance industry, focusing on CAR T-cell therapy and regulatory compliance.
U.S. Pediatric Uninsured Rates Rise, Impacting Child Cancer Outcomes
In 2024, over four million U.S. children were uninsured, the highest rate in a decade, worsening pediatric cancer diagnosis delays and mortality. Fragmented insurance and Medicaid enrollment gaps drive coverage loss.
CMS Negotiates Discounts on 15 Drugs, Including Cancer Therapies
CMS has secured significant price reductions on 15 drugs including costly cancer treatments, impacting Medicare Part B pricing and healthcare costs.
ASTRO Supports Prior Authorization Reform in Medicare Advantage to Improve Cancer Care
ASTRO backs bipartisan legislation to reform Medicare Advantage prior authorization, aiming to reduce cancer treatment delays and improve care outcomes.
Medicare Caps Oral Cancer Drug Costs and Expands Payment Options in 2025
New Medicare Part D rules in 2025 cap oral cancer drug costs at $2,000 annually and introduce a voluntary monthly payment plan to improve affordability for patients.